OBJECTIVE: UCP2 -866G>A (rs659366) has been implicated in cardiometabolic disease and represents a novel candidate gene for beta-blocker response, particularly among patients with diabetes. We assessed the function of -866G>A and its role as a modifier of beta-blocker treatment outcomes by diabetes status in an acute coronary syndrome (ACS) cohort. METHODS: ACS patients with genetic samples and 12 months of follow-up for cardiac rehospitalizations or death (n=468) were assessed. The influence of -866G>A on beta-blocker treatment outcomes was evaluated in those with diabetes and without. To assess functional correlates of -866G>A, we compared uncoupling protein 2 (UCP2) expression in the skeletal muscle of obese participants by genotype and compared the activity of UCP2 luciferase promoters with -866G and -866A alleles. RESULTS: An interaction between -866G>A and beta-blocker treatment was found in individuals with diabetes (P=0.002) but not those without (P=0.79). Among G/G individuals with diabetes, discharge beta-blocker use was associated with an 80% reduction in cardiac rehospitalization (adjusted hazard ratio: 0.20; 95% confidence interval: 0.04-1.02). In contrast, among A-carrier patients with diabetes, there was an 11-fold increase in cardiac rehospitalizations with discharge beta-blocker therapy (adjusted hazard ratio: 11.75; 95% confidence interval: 1.28-108.2). Promoter activity assays showed that -866G had greater cyclic AMP response element binding protein-responsiveness compared with -866A, and compared with -866A carriers G/G individuals exhibited increased UCP2 expression in the skeletal muscle. CONCLUSION: We identified a significant interaction between -866G>A and beta-blocker response among ACS patients with diabetes. Furthermore, -866G conferred greater gene transcriptional activity than -866A in cell lines and in obese patients. These findings may help us gain insight into the mechanisms underlying the beneficial and detrimental effects of beta-blockers in those with diabetes.
OBJECTIVE:UCP2 -866G>A (rs659366) has been implicated in cardiometabolic disease and represents a novel candidate gene for beta-blocker response, particularly among patients with diabetes. We assessed the function of -866G>A and its role as a modifier of beta-blocker treatment outcomes by diabetes status in an acute coronary syndrome (ACS) cohort. METHODS: ACS patients with genetic samples and 12 months of follow-up for cardiac rehospitalizations or death (n=468) were assessed. The influence of -866G>A on beta-blocker treatment outcomes was evaluated in those with diabetes and without. To assess functional correlates of -866G>A, we compared uncoupling protein 2 (UCP2) expression in the skeletal muscle of obeseparticipants by genotype and compared the activity of UCP2 luciferase promoters with -866G and -866A alleles. RESULTS: An interaction between -866G>A and beta-blocker treatment was found in individuals with diabetes (P=0.002) but not those without (P=0.79). Among G/G individuals with diabetes, discharge beta-blocker use was associated with an 80% reduction in cardiac rehospitalization (adjusted hazard ratio: 0.20; 95% confidence interval: 0.04-1.02). In contrast, among A-carrier patients with diabetes, there was an 11-fold increase in cardiac rehospitalizations with discharge beta-blocker therapy (adjusted hazard ratio: 11.75; 95% confidence interval: 1.28-108.2). Promoter activity assays showed that -866G had greater cyclic AMP response element binding protein-responsiveness compared with -866A, and compared with -866A carriers G/G individuals exhibited increased UCP2 expression in the skeletal muscle. CONCLUSION: We identified a significant interaction between -866G>A and beta-blocker response among ACS patients with diabetes. Furthermore, -866G conferred greater gene transcriptional activity than -866A in cell lines and in obesepatients. These findings may help us gain insight into the mechanisms underlying the beneficial and detrimental effects of beta-blockers in those with diabetes.
Authors: Franz Krempler; Harald Esterbauer; Raimund Weitgasser; Christoph Ebenbichler; Josef R Patsch; Karl Miller; Mingqiang Xie; Veronika Linnemayr; Hannes Oberkofler; Wolfgang Patsch Journal: Diabetes Date: 2002-11 Impact factor: 9.461
Authors: H Esterbauer; C Schneitler; H Oberkofler; C Ebenbichler; B Paulweber; F Sandhofer; G Ladurner; E Hell; A D Strosberg; J R Patsch; F Krempler; W Patsch Journal: Nat Genet Date: 2001-06 Impact factor: 38.330
Authors: Hua Wang; Winston S Chu; Tong Lu; Sandra J Hasstedt; Philip A Kern; Steven C Elbein Journal: Am J Physiol Endocrinol Metab Date: 2003-08-12 Impact factor: 4.310
Authors: Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein Journal: Proc Natl Acad Sci U S A Date: 2009-08-24 Impact factor: 11.205
Authors: Vinciane Gaussin; James E Tomlinson; Christophe Depre; Stefan Engelhardt; Christopher L Antos; Gen Takagi; Lutz Hein; James N Topper; Stephen B Liggett; Eric N Olson; Martin J Lohse; Stephen F Vatner; Dorothy E Vatner Journal: Circulation Date: 2003-11-17 Impact factor: 29.690
Authors: Sukhbir S Dhamrait; Jeffrey W Stephens; Jacqueline A Cooper; Jayshree Acharya; Ali R Mani; Kevin Moore; George J Miller; Steve E Humphries; Steven J Hurel; Hugh E Montgomery Journal: Eur Heart J Date: 2004-03 Impact factor: 29.983
Authors: Luciana Gioli-Pereira; Paulo Cjl Santos; Luisa S Sugaya; Noely E Ferreira; José Eduardo Krieger; Alexandre C Pereira; Whady A Hueb Journal: BMC Med Genet Date: 2013-03-27 Impact factor: 2.103
Authors: Bianca M de Souza; Letícia A Brondani; Ana P Bouças; Denise A Sortica; Caroline K Kramer; Luís H Canani; Cristiane B Leitão; Daisy Crispim Journal: PLoS One Date: 2013-01-24 Impact factor: 3.240